Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
about
Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCTChronic myeloid leukemia: reminiscences and dreamsCurrent status of hematopoietic stem cell transplant in chronic myeloid leukemiaSummary of the published Indian data on chronic myeloid leukemiaApplication of machine learning algorithms for clinical predictive modeling: a data-mining approach in SCT.The treatment of chronic myeloid leukemia, data from Gujarat Cancer and Research Institute, Ahmedabad.Prediction of Hematopoietic Stem Cell Transplantation Related Mortality- Lessons Learned from the In-Silico Approach: A European Society for Blood and Marrow Transplantation Acute Leukemia Working Party Data Mining Study.How to interpret the results of medical time series data analysis: Classical statistical approaches versus dynamic Bayesian network modeling.Autologous stem cell transplantation for patients with chronic myeloid leukemia. The Argentine Group of Bone Marrow Transplantation (GATMO) experience.Case-matched comparison with standard versus reduced intensity conditioning regimen in chronic myeloid leukemia patients.Dynamic International Prognostic Scoring System scores, pre-transplant therapy and chronic graft-versus-host disease determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis.Use of the quality management system "JACIE" and outcome after hematopoietic stem cell transplantationThe prognostic value of serum C-reactive protein, ferritin, and albumin prior to allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndromesEarly prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemiaAllogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia.A modified EBMT risk score and the hematopoietic cell transplantation-specific comorbidity index for pre-transplant risk assessment in adult acute lymphoblastic leukemia.Impact of genomic risk factors on outcome after hematopoietic stem cell transplantation for patients with chronic myeloid leukemia.Insufficient recovery of thymopoiesis predicts for opportunistic infections in allogeneic hematopoietic stem cell transplant recipients.Advances in the treatment of chronic myeloid leukemia.Hematopoietic stem cell transplantation for leukemiaChronic myelogenous leukaemia.Predicting relapse prior to transplantation in chronic myeloid leukemia by integrating expert knowledge and expression dataSecondary recurrent miscarriage and H-Y immunity.Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia.Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation.Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations.Trends in the treatment changes and medication persistence of chronic myeloid leukemia in Taiwan from 1997 to 2007: a longitudinal population database analysisNCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemiaChronic myelogenous leukemia: treatment and monitoring.Sex, age, race and intervention type in clinical studies of HIV cure: a systematic review.The EBMT Risk Score in the Presence of Graft Versus Host Disease in Allogeneic Stem Cell Transplantation in Adult Acute Myelogenous Leukemia: A Multistate Model for Competing RisksPerspectives on the treatment of chronic phase and advanced phase CML and Philadelphia chromosome positive ALL(1).Current CML therapy: progress and dilemma.Advances in targeted therapy for chronic myeloid leukemia.STI571 as a targeted therapy for CML.Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation in myeloid diseases.Transplantation for chronic myelogenous leukemia: yes, no, maybe so. . . An Oregon perspective.The interplay between cell adhesion cues and curvature of cell adherent alginate microgels in multipotent stem cell culture.Graft-versus-host disease prophylaxis after transplantation: a network meta-analysis.Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies
P2860
Q24685958-2999D3D4-239B-46C5-ADF2-B32C26584688Q26748769-9918536B-5DD4-4BF4-8D72-4E2E140434A9Q27010475-4E70C603-CDD8-4091-A3A4-51CC4AB88ABFQ28075574-AD11277B-B219-481B-8181-E66E185448B5Q30671533-722C1BE0-AFC2-4A6C-970A-AB1B4C9D20F2Q30754830-34FA2FD8-90AF-4762-8673-5EF397EB8176Q31052875-FCD0E05B-51F9-47A4-8D58-C3A348057CC9Q31159691-99861797-CE48-41D0-89F1-D2E21BE6288FQ33345338-C65448B4-A6E9-452A-8C77-ABFC23DD8781Q33397477-015226D1-44F9-4F91-B6A2-40B87A8DC59DQ33400683-C7E70A8B-1917-4E64-9248-EBCC10BF2ED2Q33558733-F06E27BD-C3D3-4426-BEE6-642AEE80DCEFQ33573495-9B467292-D015-47F5-973C-080AB12BBDA1Q33632220-E87C021C-9A63-4747-A156-B7BD90ECA309Q33706393-E491DDC3-A041-4249-BBB7-3558C815CBC0Q33829105-94F4793F-BAA1-4E7B-9DF4-90670975491AQ33886172-6476C982-F53A-4974-A92A-05814DD0CCF9Q34000647-20EFD93C-F717-4BC5-9C3A-1DEFEFB103DAQ34002977-55B449C1-68F7-4CA0-93ED-C405F1590452Q34034180-6A5BDE91-F26B-4B5C-B333-EDA87CAB1DC8Q34135279-C297E57D-A9FC-49D5-B075-1974725260E3Q34148173-3720AA79-724A-4D5A-A54C-BA14291C1132Q34177424-09EF57C3-7743-456A-B6DC-453C432EA579Q34198055-4130003A-E49F-47C4-934A-1C9668B4E53EQ34260505-A685603F-7186-4FEE-98E5-7E168C63C5D9Q34293414-AC9891BC-4E5A-411E-B6FF-820E6736E7B5Q34445704-B58D7149-FC6A-4D65-8C72-C26A9034E94AQ34522789-D4EB89F4-09C4-4A5A-8C3F-2815B22E7814Q34617628-9FC5437C-BD46-44E3-B852-161D36F1FBA4Q34870233-0ABA7123-82D5-44FB-BDA0-90DB297609F4Q35009266-3B992413-881B-4A3D-8040-C10716EC097FQ35102183-A4EEF6B5-80C0-4A9E-82BB-FF61B6AD734EQ35134977-CB267893-83FC-4B74-A6E3-0A6E18EA66A5Q35160190-F21F239F-A3C5-4AEE-8463-B95FD7ABF74DQ35193288-6E70A39D-6070-4B41-898B-FBA2BE0336F8Q35196663-1CD2DAA0-D756-47B6-9690-3711C025C2EAQ35207088-680756AE-E966-4964-A7C0-AD252AB49902Q35476810-51F39BA2-5A58-4F27-B155-9DFFC6EEE0CAQ35499395-CE1D8A69-81EE-4E28-AF29-F82528AB361DQ35554703-577FCC95-F9B5-434F-94D0-96BA0C95AC04
P2860
Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh
1998年學術文章
@zh-hant
name
Risk assessment for patients w ...... od and Marrow Transplantation.
@en
Risk assessment for patients w ...... od and Marrow Transplantation.
@nl
type
label
Risk assessment for patients w ...... od and Marrow Transplantation.
@en
Risk assessment for patients w ...... od and Marrow Transplantation.
@nl
prefLabel
Risk assessment for patients w ...... od and Marrow Transplantation.
@en
Risk assessment for patients w ...... od and Marrow Transplantation.
@nl
P2093
P921
P1433
P1476
Risk assessment for patients w ...... od and Marrow Transplantation.
@en
P2093
A Devergie
A Gratwohl
D Niederwieser
E Carreras
F Frassoni
J Apperley
J M Goldman
P304
P356
10.1016/S0140-6736(98)03030-X
P407
P577
1998-10-01T00:00:00Z